IP Verse

Methods For Multi-Resolution Analysis Of Cell-Free Nucleic Acids - EP3461274

The patent EP3461274 was granted to Guardant Health on Nov 4, 2020. The application was originally filed on Sep 29, 2017 under application number EP17857586A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3461274

GUARDANT HEALTH
Application Number
EP17857586A
Filing Date
Sep 29, 2017
Status
Granted And Under Opposition
Oct 2, 2020
Publication Date
Nov 4, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

MARGARET DIXONAug 4, 2021MEWBURN ELLISADMISSIBLE

Patent Citations (10) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
EXAMINATIONUS2016281161
EXAMINATIONWO2013190441
INTERNATIONAL-SEARCH-REPORTUS2012208706
INTERNATIONAL-SEARCH-REPORTUS2014287408
OPPOSITIONUS2012208706
OPPOSITIONWO2010127186
OPPOSITIONWO2013123442
OPPOSITIONWO2014151117
SEARCHUS2016046986
SEARCHUS2016281166

Non-Patent Literature (NPL) Citations (15) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
INTERNATIONAL-SEARCH-REPORT- STATHAM et al., "Genome-wide nucleosome occupancy and DNA methylation profiling of four human cell lines", Genomics Data, (20150300), vol. 3, pages 94 - 96, XP055501304 [Y] 4 * , abstract, pg 96,col 1, para 2, Figs 1-2 *
OPPOSITION- Agilent Technologies, "SureSelect Target Enrichment from sample to analysis", Agilent SureSelect Brochure, (20110730), pages 1 - 8, XP055923145
OPPOSITION- JAHR S et al., "DNA Fragments in the Blood Plasma of Cancer Patients: Quantitations and Evidence for Their Origin from Apoptotic and Necrotic Cells", Cancer Res, (20010202), vol. 61, no. 4, pages 1659 - 1665, XP002494286
OPPOSITION- "SureSelect DNA advanced wizard: Upload Probes", (20210802), URL: https://earray.chem.agilent.com/suredesign/help/SureSelect_advanced_wizard_Add_Review_Content_Probe_Upload.htm
OPPOSITION- Snyder et al., "Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin", Cell, Amsterdam NL , (20160114), vol. 164, no. 1, doi:10.1016/j.cell.2015.11.050, ISSN 0092-8674, pages 57 - 68, XP029385484
OPPOSITION- Frampton et al., "Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing", Nature Biotechnology, New York, (20131101), vol. 31, no. 11, doi:10.1038/nbt.2696, ISSN 1087-0156, pages 1023 - 1031, XP037113458
OPPOSITION- Leticia De Mattos-Arruda et al., "Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma", Nature Communications, (20151201), vol. 6, no. 1, doi:10.1038/ncomms9839, XP055531832
OPPOSITION- Newman et al., "An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage", Nature Medicine, New York, (20140501), vol. 20, no. 5, doi:10.1038/nm.3519, ISSN 1078-8956, pages 548 - 554, XP055580741
OPPOSITION- Newman et al., "Online supplementary material for "An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage"", Nature Medicine, doi:10.1038/nm.3519, pages 1 - 22, URL: https://media.nature.com/original/nature-assets/nm/journal/v20/n5/extref/nm.3519-S1.pdf, (20180322), XP055462152
OPPOSITION- H. C. Fan, Y. J. Blumenfeld, U. Chitkara, L. Hudgins, S. R. Quake, "Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood", Proceedings of the National Academy of Sciences, (20081021), vol. 105, no. 42, doi:10.1073/pnas.0808319105, ISSN 0027-8424, pages 16266 - 16271, XP055687023
OPPOSITION- Mckerrell et al., "Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies The Center for the Study of Haematological Malignancies", Blood, (20160707), vol. 128, no. 1, doi:10.1182/blood-2015-11-, pages e1 - e9, XP055923010
OPPOSITION- RAMOS E et al., "Population-based rare variant detection via pooled exome or custom hybridization capture with or without individual indexing", BMC Genomics, (20121206), vol. 13, doi:10.1186/1471-2164-13-683, page 683, XP021134772
OPPOSITION- Aird et al., "Analyzing and minimizing PCR amplification bias in Illumina sequencing libraries", Genome Biology, (20110221), vol. 12, no. 2, doi:10.1186/gb-2011-12-2-r18, ISSN 1465-6906, page R18, XP021091793
OPPOSITION- Richard B. Lanman et al., "Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA", PLOS ONE, (20151001), vol. 10, no. 10, doi:10.1371/journal.pone.0140712, page e0140712, XP055403636
SEARCH- RICHARD B. LANMAN ET AL, "Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA", PLOS ONE, (20151001), vol. 10, no. 10, doi:10.1371/journal.pone.0140712, page e0140712, XP055403636 [A] 1-15 * abstract * * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents